ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

BCG is one of the most widely used vaccines worldwide. However, because BCG is a biologic drug that uses benign bacteria, it is more complicated to manufacture than many other types of drugs.

“I’m pleased U.S. Urology is at the forefront of offering rBCG and would like to thank ImmunityBio for their initiative to seek and secure authorization from the FDA for expanded ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...

Anktiva becomes another option for BCG-unresponsive BMIBC patients alongside MSD/Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) – approved by the FDA in 2020 – and Ferring Pharma’s ...

The FDA approval makes Adstiladrin the first gene therapy to be approved for adult patients with high-risk BCG-unresponsive NMIBC with CIS. Ferring aims to make the drug widely accessible to ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

For years, medtech firms around the globe (and certainly European companies) introduced their products in Europe, which requires obtaining a CE ...